MET and non-small cell lung carcinoma: Indeed, in untreated NSCLC patients, low-/intermediate-level MET-GCNG/GA is often accompanied by co-mutations in other oncogenic drivers and is less sensitive to MET-signaling inhibition by MET-TKIs, as opposed to NSCLCs with high-level MET-GCNG/GA, which at baseline are less likely to harbor other detectable oncogenic drivers and are associated with significantly higher RR to MET-TKIs [4,5,16,23,24].